Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
11 p, 1.0 MB ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer / Cedó, Lidia (Institut d'Investigació Biomèdica Sant Pau) ; García León, Annabel (Institut d'Investigacions Biomèdiques Sant Pau) ; Baila Rueda, Lucía (Hospital Universitario Miguel Servet) ; Santos, David (Institut d'Investigacions Biomèdiques Sant Pau) ; Grijalva, Victor (University of California. Department of Medicine) ; Martínez Cignoni, Melanie Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Carbó, José María (Universitat de Barcelona) ; Metso, Jari (Minerva Foundation Institute for Medical Research) ; López Vilaró, Laura (Institut d'Investigacions Biomèdiques Sant Pau) ; Zorzano Olarte, Antonio (Institute for Research in Biomedicine) ; Valledor, Annabel F. (Universitat de Barcelona) ; Cenarro, Ana (Hospital Universitario Miguel Servet) ; Jauhiainen, Matti (Minerva Foundation Institute for Medical Research) ; Lerma Puertas, Enrique (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Fogelman, Alan M. (University of California. Department of Medicine) ; Reddy, Srinivasa T. (University of California. Department of Medicine) ; Escolà-Gil, Joan Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. [...]
2016 - 10.1038/srep36387
Scientific Reports, Vol. 6 (November 2016) , art. 36387  
2.
15 p, 4.6 MB Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease / Zarei, Mohammad (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ; Barroso, Emma (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ; Palomer, Xavier (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ; Dai, Jianli (University of the Chinese Academy of Sciences. Institute for Nutritional Sciences. Key Laboratory of Nutrition and Metabolism,) ; Rada, Patricia (Instituto de Salud Carlos III. Centro de Investigación Biomédica en Red) ; Quesada-López, Tania (Universitat de Barcelona. Departament de Bioquímica i Biomedicina Molecular) ; Escolà-Gil, Joan Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biología Molecular) ; Cedó, Lidia (Institut d'Investigació Biomèdica Sant Pau) ; Zali, Mohammad Reza (Shahid Beheshti University of Medical Sciences. Research Institute for Gastroenterology and Liver Diseases) ; Molaei, Mahsa (Shahid Beheshti University of Medical Sciences. Research Institute for Gastroenterology and Liver Diseases) ; Dabiri, Reza (Semnan University of Medical Sciences. lnternal Medicine Department) ; Vázquez, Santiago (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ; Pujol, Eugènia (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica) ; Valverde, Ángela M. (Instituto de Investigaciones Biomédicas Alberto Sols) ; Villarroya, Francesc (Universitat de Barcelona. Departament de Bioquímica i Biomedicina Molecular) ; Liu, Yong (Wuhan University. Institute for Advanced Studies) ; Wahli, Walter (Nanyang Technological University. Lee Kong Chian School of Medicine) ; Vázquez-Carrera, Manuel (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica)
The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)β/δ and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. [...]
2018 - 10.1016/j.molmet.2017.12.008
Molecular metabolism, Vol. 8 (Feb. 2018) , p. 117-131  

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.